MeSH D006009 - glycogen storage disease type ii
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Sanofi | Alglucosidase alfa | Lumizyme | 2010-05-24 | |||
| Alglucosidase alfa | Myozyme | 2006-04-28 | ||||
| Avalglucosidase alfa | Nexviadyme | 2022-06-24 | ||||
| Avalglucosidase alfa | Nexviazyme | 2021-08-06 | ||||
| Amicus Therapeutics | Cipaglucosidase alfa | Pombiliti | 2023-03-20 | |||
| Miglustat | Opfolda | 2023-06-26 |
Clinical Trials
Historical Success Rate
Phase 1
39%9/23
Phase 2
83%5/6
Phase 3
62%8/13
Approved: 4Overall Success rate: 20%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use